IL151163A0 - Use of cdp-choline for the treatment of alcohol withdrawal syndrome - Google Patents

Use of cdp-choline for the treatment of alcohol withdrawal syndrome

Info

Publication number
IL151163A0
IL151163A0 IL15116301A IL15116301A IL151163A0 IL 151163 A0 IL151163 A0 IL 151163A0 IL 15116301 A IL15116301 A IL 15116301A IL 15116301 A IL15116301 A IL 15116301A IL 151163 A0 IL151163 A0 IL 151163A0
Authority
IL
Israel
Prior art keywords
choline
cdp
treatment
alcohol withdrawal
withdrawal syndrome
Prior art date
Application number
IL15116301A
Other languages
English (en)
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of IL151163A0 publication Critical patent/IL151163A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
IL15116301A 2000-03-29 2001-03-28 Use of cdp-choline for the treatment of alcohol withdrawal syndrome IL151163A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200000765A ES2170649B1 (es) 2000-03-29 2000-03-29 Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica.
PCT/EP2001/003536 WO2001072288A2 (en) 2000-03-29 2001-03-28 Use of cdp-choline for the treatment of alcohol withdrawal syndrome

Publications (1)

Publication Number Publication Date
IL151163A0 true IL151163A0 (en) 2003-04-10

Family

ID=8492914

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15116301A IL151163A0 (en) 2000-03-29 2001-03-28 Use of cdp-choline for the treatment of alcohol withdrawal syndrome
IL151163A IL151163A (en) 2000-03-29 2002-08-09 Use of cdp-choline for the preparation of a medicament for treating alcohol withdrawal syndrome

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL151163A IL151163A (en) 2000-03-29 2002-08-09 Use of cdp-choline for the preparation of a medicament for treating alcohol withdrawal syndrome

Country Status (21)

Country Link
US (1) US6894032B2 (enExample)
EP (1) EP1267892B1 (enExample)
JP (1) JP4724348B2 (enExample)
KR (1) KR100794891B1 (enExample)
AT (1) ATE281172T1 (enExample)
AU (2) AU2001262141B2 (enExample)
BR (1) BR0109477A (enExample)
CA (1) CA2402707C (enExample)
CZ (1) CZ298933B6 (enExample)
DE (1) DE60106890T2 (enExample)
DK (1) DK1267892T3 (enExample)
ES (1) ES2170649B1 (enExample)
IL (2) IL151163A0 (enExample)
MX (1) MXPA02009442A (enExample)
NO (1) NO329766B1 (enExample)
NZ (1) NZ520825A (enExample)
PL (1) PL199291B1 (enExample)
PT (1) PT1267892E (enExample)
RU (1) RU2251422C2 (enExample)
WO (1) WO2001072288A2 (enExample)
ZA (1) ZA200206349B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030294B2 (en) 2000-03-16 2011-10-04 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
EP1541154A1 (en) * 2002-07-11 2005-06-15 Yamasa Corporation Medicinal composition for drug-induced neuropathy
CN100430066C (zh) 2002-11-08 2008-11-05 麦克莱恩医院 用于烟草依赖性和戒断治疗的化合物
AU2003299715A1 (en) * 2002-12-20 2004-07-22 The Mclean Hospital Corporation Compounds for the normalization of the sleep/wake cycle
US20050129710A1 (en) * 2003-10-08 2005-06-16 Renshaw Perry F. Methods of treating psychiatric substance abuse, and other disorders using combinations containing omega-3 fatty acids
EP1765075A4 (en) 2004-06-10 2010-11-10 Mclean Hospital Corp PYRIMIDINES, AS FORM. uridine; IN THE TREATMENT OF PATIENTS WITH MANIC-DEPRESSIVE PSYCHOSIS
WO2006020703A1 (en) 2004-08-11 2006-02-23 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308627A (en) * 1990-08-07 1994-05-03 Umbdenstock Jr Anthony J Nutritional supplement for optimizing cellular health
RU2072239C1 (ru) * 1991-01-11 1997-01-27 Институт биохимии СО РАМН Способ коррекции метаболической зависимости от алкоголя и средство л.е.панина для его осуществления
DE4342173A1 (de) * 1993-12-10 1995-06-14 Lohmann Therapie Syst Lts Pharmazeutische Formulierung zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer
CA2193967C (en) * 1994-07-01 2007-09-11 Reid W. Von Borstel Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
KR100217488B1 (ko) * 1997-06-03 1999-09-01 맹섭 골프채의 헤드커버
RU2127589C1 (ru) * 1997-06-03 1999-03-20 Порембский Ярослав Олегович Способ лечения стрессорных поражений нервной системы
US5958896A (en) * 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
US8030294B2 (en) 2000-03-16 2011-10-04 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders

Also Published As

Publication number Publication date
DK1267892T3 (da) 2005-03-07
EP1267892B1 (en) 2004-11-03
NO20024574L (no) 2002-11-22
ES2170649A1 (es) 2002-08-01
ATE281172T1 (de) 2004-11-15
WO2001072288A3 (en) 2002-05-10
EP1267892A2 (en) 2003-01-02
MXPA02009442A (es) 2003-02-12
PT1267892E (pt) 2005-03-31
US6894032B2 (en) 2005-05-17
CZ298933B6 (cs) 2008-03-12
NZ520825A (en) 2004-04-30
BR0109477A (pt) 2003-06-03
KR20030005248A (ko) 2003-01-17
PL199291B1 (pl) 2008-09-30
AU6214101A (en) 2001-10-08
KR100794891B1 (ko) 2008-01-14
DE60106890T2 (de) 2005-11-03
NO329766B1 (no) 2010-12-13
PL363177A1 (en) 2004-11-15
ZA200206349B (en) 2003-08-08
WO2001072288A2 (en) 2001-10-04
US20030162749A1 (en) 2003-08-28
CA2402707A1 (en) 2001-10-04
ES2170649B1 (es) 2003-06-16
NO20024574D0 (no) 2002-09-24
JP4724348B2 (ja) 2011-07-13
RU2002129579A (ru) 2004-03-27
RU2251422C2 (ru) 2005-05-10
DE60106890D1 (de) 2004-12-09
AU2001262141B2 (en) 2005-03-10
CZ20023245A3 (cs) 2003-03-12
IL151163A (en) 2011-01-31
JP2003528133A (ja) 2003-09-24
CA2402707C (en) 2007-11-13

Similar Documents

Publication Publication Date Title
BR0015188A (pt) Composições farmacêuticas
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
BG104727A (en) Pharmaceutical composition of topiramate
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
YU68199A (sh) Farmaceutske formulacije koje sadrže vorikonazol
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
YU7804A (sh) Stabilni polimorf flibanserina,postupak za njegovo dobijanje u industrijskim razmerama i njegova primena za pripremanje lekova
BR0012901A (pt) Medicamentos de ß - carbolina
IL150528A0 (en) Ibuprofen containing active agent preparation
YU53402A (sh) Preparat
GEP20053617B (en) Bridged Piperazine Derivatives
SE0102440D0 (sv) New compound
IL151163A0 (en) Use of cdp-choline for the treatment of alcohol withdrawal syndrome
EP0657167A3 (fr) Application de l'oenothéine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, les compositions pharmaceutiques le contenant et un procédé de préparation à partir d'Epilobium Parviflorum.
ATE360428T1 (de) Analgetisches arzneimittel
AP1530A (en) Pharmaceutical composition for intramuscular injection containing loxoprofen.
BR0112690A (pt) Medicamento contendo cilansetron para o tratamento de pacientes ibs masculinos não-obstipativos
YU24603A (sh) Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin
MXPA03010919A (es) Uso de acetil l-carnitina para preparacion de medicamento para terapia preventiva del dolor.
AU2002220654A1 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
GEP20043356B (en) Compounds Useful For Treatment or Prevention of Diseases Mediated By Alpha- 2B-Adrenoceptor
IL140839A0 (en) Use of tiludronic acid and derivatives thereof in poultry for the preparation of a medicinal product for preventing and treating osteoporosis
ITMI20011628A0 (it) Uso della nac per la preparazione di un medicamento adatto alla somministrazione endovenosa per il trattamento del fenomeno di raynaud
ES2173044A1 (es) Glicina, n-(n-l- -glutamil-3-(nitrosotio)-l-valil) y sus aplicaciones.
BR9805026A (pt) Compostos contdndo tetrahidrolipstatina

Legal Events

Date Code Title Description
FF Patent granted